摘要:
The invention concerns compounds of formula (I) wherein A, X, Y, n, R1, R2 and R3 are as defined in Claim 1. Said compounds are specifically binding to sigma receptors particularly those of the peripheral nervous system.
摘要:
The invention concerns compounds of formula (I) wherein: R1 represents a hydrogen or halogen atom or a CF3 group; R2 and R3 independently represent a hydrogen atom or a methyl group; n and n' each independently represent 0 or 1;* represents the binding positions; A represents N or CH; X represents a sulphur or oxygen atom; R4 and R5 independently represent a hydrogen atom or a (C1-C6) alkyl group, as well as their salts or solvates. The invention also concerns a method for preparing said compounds and pharmaceutical compositions containing them.
摘要:
The invention concerns a novel use of compounds of formula (I), wherein: r3 represents a phenyl group optionally substituted or a thienyl group, for preparing medicines useful as anticancer drugs.
摘要:
The invention concerns compounds of formula (I), wherein: X represents N or CH; R1 represents a hydrogen or halogen atom or a CF3 group; R2 and R3 independently represent a hydrogen atom or a methyl group; n is 0 or 1; A represents a nitrogenous heterocycle optionally substituted; and their N-oxides and their salts or solvates, pharmaceutical compositions and medicines containing same and a method for preparing same.
摘要:
The invention concerns the use of a central cannabinoid receptor antagonist for preparing medicines for use in treating and preventing neuro-inflammatory pathologies.
摘要:
The invention concerns compounds of formula (I), wherein: X represents N or CH; R1 represents a hydrogen or halogen atom of a CF3 group; n is an integer from 1 to 5; A represents a partly saturated bicyclic or tricyclic carbon compound, as well as their salts or solvates, their N-oxides, pharmaceutical compositions containing them, a method for preparing them and synthesis intermediates in said method.
摘要:
The invention concerns compounds of formula (I) wherein: X represents N or CH; R1 represents a hydrogen or halogen atom, or a CF3 group; R2 and R3 independently represent a hydrogen atom or a methyl group; n is 0 or 1; A represents a group of formula (a) or (b) wherein: R4 represents a hydrogen or halogen atom, a C1-C4 alkyl group, a CF3 group, an amino, mono(C1-C4)alkylamino, di(C1-C4)alkylamino; R5 represents a hydrogen or halogen atom, a (C1-C4)alkoxy group, a (C1-C4)alkyl group or a CF3 group; R6 represents a hydrogen atom, a (C1-C4)alkyl group or a (C1-C4)alkoxy group; and their salts or solvates, pharmaceutical compositions containing them, a method for preparing them and the synthesis intermediates in said method.
摘要:
The invention concerns a compound of formula (I), wherein: X represents N or CH; R1 represents a hydrogen or halogen atom or a CF3 group; R2 and R3 independently represent a hydrogen atom or a C1-C4 alkyl group; R4 represents a hydrogen atom or a C1-C4 alkyl group; n is 0 or 1; A represents a heterocycle selected among pyridine, pyrimidine, pyrazine and pyridazine optionally mono-or di-substituted by a C1-C4 alkyl or C1-C4 alkoxy group; and their N-oxides and their salts or solvates.
摘要:
The invention concerns the use of tetrahydropyridine derivatives of formula (I) in which: R1 represents a halogen or a CF3, (C1-C4) alkyl or (C1-C4)alkoxy group; Y represents a nitrogen atom or a CH group; Z' and Z" represent each hydrogen or a (C1-C3) alkyl group, or one represents hydrogen and the other a hydroxy group, or both together represent an oxo group; Z represents a phenyl radical; a phenyl radical monosubstituted by a substituent X, X being (a) a (C1-C6)alkyl, (C1-C6)alkoxy (C3-C7)carboxyalkyl, (C1-C4)alkoxycarbonyl(C1-C6)alkyl, (C3-C7)carboxyalkoxy or (C1-C4)-alkoxycarbonyl(C1-C6) alkoxy group; (b) a group selected among a (C3-C7)cycloalkyl, (C3-C7)cycloalkoxy, (C3-C7)cycloalkylmethyl, (C3-C7)cycloalkylamino and cyclohexenyl group, said group capable of being substituted by a halogen, hydroxy, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, amino, mono- or di-(C1-C4)alkylamino; or (c) a group selected among a phenyl, phenoxy, phenylamino, N-(C1-C3)alkylphenylamino, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulphonyl, phenylsulphinyl or styryl group, said group can be mono- or polysubstituted on the phenyl group by a halogen, CF3, (C1-C4)alkyl, (C1-C4)alkoxy, cyano, amino, mono- or di-(C1-C4)alkylamino, (C1-C4)acylamino, carboxy, (C1-C4)alkoxycarbonyl, aminocarbonyl, mono- or di-(C1-C4)alkylaminocarbonyl, amino(C1-C4)alkyl hydroxy(C1-C4)alkyl or halogeno(C1-C4)alkyl; a phenyl radical disubstituted by a substituent R2, R2 being a halogen or a hydroxy, methyl, ethyl, (C3-C6)alkyl, (C1-C4)alkoxy or trifuoromethyl group and by a substituent X, X being as defined above; a 1-naphthyl or 2-naphthyl radical; a 1-naphthyl or 2-naphthyl radical, substituted in positions 5, 6, 7 and/or 8 by one or two hydroxyl groups, one or two (C1-C4) alkoxy groups, or a 6,7-methylenedioxy group; or Z" is hydrogen and Z and Z' represent, each independently, a phenyl group non-substituted or mono-, di- or trisubstituted; or one of its pharmaceutically acceptable salts or solvates, for preparing pharmaceutical compositions to fight against diseases causing demyelination.
摘要:
The invention concerns compounds of formula (I), wherein: X represents N or CH; R1 represents a hydrogen or halogen atom or a CF3 group; R2 and R3 independently represent a hydrogen atom or a methyl group; n is 0 or 1; A represents a condensed heterocyclic group of formula (W) wherein W completes a ring with 6 atoms, aromatic or saturated containing 1 or 2 nitrogen atoms or a ring with 5 atoms, aromatic or saturated containing a nitrogen, oxygen or sulphur atom optionally substituted; and their N-oxides and their salts or solvates, pharmaceutical compositions and medicines containing same and a method for preparing same.